Related Experiment Videos
Systemic therapy of metastatic breast cancer
1Department of Oncology R, Odense University Hospital, Denmark.
Abstract:
Recent research has produced several new options for endocrine treatment of metastatic breast cancer. Among these, tamoxifen has become the most commonly used endocrine therapy for metastatic breast cancer due to its few side effects and an overall response rate of 35%. Despite an obvious clinical rationale for combined endocrine therapy, most trials have failed to show any benefit. Although data from trials combining tamoxifen with prednisolone or androgens seem promising, the use of combined endocrine therapy still has to be considered experimental. In patients with metastatic breast cancer, a combination of cytotoxic and endocrine therapy generally leads to a higher rate of remission than in patients treated with either modality alone. The increase in rate of response, however, is not followed by an increase in survival. The combined approach should therefore be explored further in randomized trials, preferably based upon a better understanding of tumor cell kinetics.
Insights
Tamoxifen is a common endocrine therapy for metastatic breast cancer, showing a 35% response rate. Combined therapies show promise but require further research to improve survival outcomes.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Metastatic breast cancer treatment options are evolving.
- Tamoxifen is a widely used endocrine therapy with a 35% response rate and manageable side effects.
- Combined endocrine therapies have shown limited success in trials despite theoretical benefits.
Purpose of the Study:
- To review current endocrine treatment options for metastatic breast cancer.
- To evaluate the efficacy and limitations of combined endocrine therapies.
- To discuss the role of combination cytotoxic and endocrine therapy.
Main Methods:
- Literature review of recent research on endocrine treatments for metastatic breast cancer.
- Analysis of clinical trial data for tamoxifen and combined endocrine therapies.
- Examination of studies combining cytotoxic and endocrine modalities.
Main Results:
- Tamoxifen is effective with a 35% response rate in metastatic breast cancer.
- Most combined endocrine therapy trials have not demonstrated significant benefits.
- Combination cytotoxic and endocrine therapy increases remission rates but not survival.
Conclusions:
- Combined endocrine therapy for metastatic breast cancer remains experimental.
- Further randomized trials are needed to explore combined cytotoxic and endocrine approaches.
- A deeper understanding of tumor cell kinetics is crucial for optimizing combination therapies.